We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biosensor Integrated in Active Microfluidic Cartridge Allows Superior Screening Possibilities

By LabMedica International staff writers
Posted on 06 Jan 2010
A polymer-based sensor integrated into an active microfluidic cartridge will allow simpler, faster, and systematic screening possibilities. More...
The new concept for diagnosis will permit, for example, doctors to diagnose a disease such as cancer, using only few microliters of blood taken from a patient.

The integration of sensing functionality as well as assay functionality into a compact fully-integrated cartridge-like device allowed transferring complexity from the macro to the micro system, leading to a Lab-on a-Chip. A polymer based technology platform was developed; it applies a label-free optical detection based on surface plasmon resonance (SPR).

Integrated into the cartridge the optical components (light source, waveguide, and detector) and fluidic elements for active liquid transport make it very suitable for diagnostics. The final product will be manufactured using large scale, mass production techniques resulting in a cartridge that will be inexpensive, disposable, and sensitive.

The polymer-based sensor the Plasmon enhanced SPR is being developed by the Surface Enhanced Micro Optical Fluidic Systems (SEMOFS) project (Chemnitz, Germany), supported by the European Commission with EUR 1.9 million in funding. The consortium of the project involves multidisciplinary expertise split among eight partners from five European countries, Switzerland, Belgium, Germany, France, and the UK.

SEMOFS was finished in February 2009, and tangible achievements have been reached. The hardware components of the integrated approach are technically operable. The cost estimations show that the cost target of less than EUR 50 is within reach. The concept is considered as being feasible for the new integrated biosensor approach. Some of the aspects targeted in the project need to be studied in more detail; these include the integration of all components into a single device to allow for example, clinical testing for cancer.

In order to begin utilizing project results it will be necessary to apply the components in several different applications, such as: excitation, microfluidic, polymer photodiode array for the low cost spectrometer, fast optimization in plasmonic devices design, and surface coating.

Related Links:
SEMOFS



Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.